TY - JOUR
T1 - Bacteriological and clinical studies of cefozopran
AU - Okada, Kaoru
AU - Kumagai, Yukio
AU - Takaki, Koji
AU - Shimono, Nobuyuki
AU - Misumi, Hiroyasu
AU - Eguchi, Katsuhiko
AU - Shigematsu, Mika
AU - Niho, Yoshiyuki
AU - Sawae, Yoshiro
AU - Ninomiya, Kiyoshi
PY - 1993
Y1 - 1993
N2 - We performed bacteriological and clinical studies on Cefozopran (CZOP), a new cephalosporin antibiotic, with the following results. 1. Antimicrobial activity The MICs of CZOP against various clinical isolates were determined with an inoculum size of 106 cells/ml. MIC90 was 0.10 μg/ml against Eschemichia coli, 0.39 against Klebsiella pneumoniae, 0.78 against Enterobacter spp., 3.13 against Methicillin-resistant Staphylococcus aureus, 6.25 against Citrobacter freuindii, 12.5 against Pseudomonas aeruginosa, and 25 against Enterococcus faecalis. Its activity was more potent than control drugs ; cefuzonam, ceftazidime and cefotaxime. MIC90 of CZOP for H. influenzae was 0.39 μg/ml, but it was less active than those of the control drugs. 2. Clinical efficacy Five patients with pneumonia, including 1 with acute bronchitis, and 1 with acute tonsillitis were treated with CZOP at a daily dose of 1.0∼3.0 g for 3∼16 days. Clinical response was good in 5, fair in 1, and poor in one patient. Exanthema was seen in one patient, and elevation of GPT and eosinophilia were observed in 2, and 3 patients, respectively.
AB - We performed bacteriological and clinical studies on Cefozopran (CZOP), a new cephalosporin antibiotic, with the following results. 1. Antimicrobial activity The MICs of CZOP against various clinical isolates were determined with an inoculum size of 106 cells/ml. MIC90 was 0.10 μg/ml against Eschemichia coli, 0.39 against Klebsiella pneumoniae, 0.78 against Enterobacter spp., 3.13 against Methicillin-resistant Staphylococcus aureus, 6.25 against Citrobacter freuindii, 12.5 against Pseudomonas aeruginosa, and 25 against Enterococcus faecalis. Its activity was more potent than control drugs ; cefuzonam, ceftazidime and cefotaxime. MIC90 of CZOP for H. influenzae was 0.39 μg/ml, but it was less active than those of the control drugs. 2. Clinical efficacy Five patients with pneumonia, including 1 with acute bronchitis, and 1 with acute tonsillitis were treated with CZOP at a daily dose of 1.0∼3.0 g for 3∼16 days. Clinical response was good in 5, fair in 1, and poor in one patient. Exanthema was seen in one patient, and elevation of GPT and eosinophilia were observed in 2, and 3 patients, respectively.
UR - http://www.scopus.com/inward/record.url?scp=0027746328&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027746328&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.41.Supplement4_227
DO - 10.11250/chemotherapy1953.41.Supplement4_227
M3 - Article
AN - SCOPUS:0027746328
SN - 0009-3165
VL - 41
SP - 227
EP - 232
JO - Chemotherapy
JF - Chemotherapy
ER -
